Search
Fimasartan
go.drugbank.com/drugs/DB09279InvestigationalFimasartan is an angiotensin II receptor antagonist (ARB) drug employed in the treatment of both hypertension and heart failure. … It has been found to be safe when administered with hydrochlorothiazide (a diuretic) in clinical trials.
Mixtures: DI-ARAHKOR, ARAHKOR DUOCategories: Agents Acting on the Renin-Angiotensin SystemOlipudase alfa
go.drugbank.com/drugs/DB12835ApprovedInvestigational[A251590] It was later approved by the European Commission on June 28, 2022 [L42740] and by the FDA on August 31, 2022.[L43145] … [A251590] Olipudase alfa gained its first global approval in Japan on March 28, 2022.
Naxitamab
go.drugbank.com/drugs/DB15965ApprovedInvestigationalthe administration of naxitamab therapy markedly simpler than that of its predecessor. … [L24929] Naxitamab-gqgk (Danyelza) was granted accelerated approval by the FDA in November 2020 for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow.
Dacomitinib
go.drugbank.com/drugs/DB11963ApprovedInvestigational[A40009] Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018. … binding at the ATP domain of the epidermal growth factor receptor family kinase domains.
Sotagliflozin
go.drugbank.com/drugs/DB12713ApprovedInvestigational[L39739] On March 22, 2022, the marketing authorization of sotagliflozin for the treatment of type 1 diabetes mellitus was withdrawn by the EMA due to commercial reasons. … Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, the first of its kind,[A244499] which is approved for use in the EU, in combination with insulin, to improve glycemic control in patients with type
Categories: Drugs Used in DiabetesOmega-3-carboxylic acids
go.drugbank.com/drugs/DB09568ApprovedWithdrawn[A25808] It was developed by AstraZeneca Pharmaceuticals and firstly approved by the FDA on May 05, 2014.[L2386] … The omega-3 carboxylic acid (OM3-CA) is a new formulation of omega-3 fatty acids that present an enhanced bioavailability in the treatment of dyslipidemia.
Irofulven
go.drugbank.com/drugs/DB05786InvestigationalA novel anti-cancer compound synthesized by scientists at the University of California, San Diego more than a decade ago from toxins of the poisonous jack-o-lantern mushroom, has been granted “fast track … Food and Drug Administration (FDA) after demonstrating promise against one of the most deadly cancers.
Datopotamab deruxtecan
go.drugbank.com/drugs/DB16410ApprovedInvestigational[L52215] Datopotamab deruxtecan-dlnk (Datroway) was approved by the US FDA in January 2025 for the treatment of hormone receptor positive, HER2 negative unresectable or metastatic breast cancer. … [L52130,L52220] In June 2025, it was granted an accelerated approval by the FDA for the treatment non-small cell lung cancers with EGFR mutations.[L53623]
Tamoxifen
go.drugbank.com/drugs/DB00675ApprovedInvestigational[A1026] Tamoxifen was granted FDA approval on 30 December 1977.[L7799] … [A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.
Synonyms: (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine, (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamineInternational brands: Nolvadex-DDesflurane
go.drugbank.com/drugs/DB01189ApprovedInvestigationalIt was developed in the late 1980s out of a need for a more rapidly acting and rapidly cleared inhaled anesthetic.[A226883,A226888] Desflurane was granted FDA approval on 18 September 1992.[L30285] … Desflurane, or I-653, a a volatile anesthetic that is more rapidly cleared and less metabolized than previous inhaled anesthetics such as [methoxyflurane], [sevoflurane], [enflurane], or [isoflurane].